- 66 次围观
产品图片
货号/SKU
NR-52392
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-52392?? Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana)(Monoclonal Antibodies)|SARS Coronavirus|Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana)| -60°C or colder |Novici Biotech LLCAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana), NR-52392.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
Antibody Class: IgG1
Human monoclonal antibody CR3022 was prepared via an immune phage display library, constructed from lymphocytes of a convalescent severe acute respiratory syndrome coronavirus (SARS-CoV) patient. CR3022 is a neutralizing antibody that targets the receptor binding domain (RBD) of the spike (S) glycoprotein of SARS-CoV. NR-52392 was produced in Nicotiana benthamiana tobacco plants using a transient plant expression system and purified from the extracellular fraction using protein A chromatography. Plant-made antibody CR3022 features complementarity-determining region (CDR) sequences introduced into a human IgG1 molecule. The epitope of CR3022 does not overlap with the ACE2-binding site within the S glycoprotein RBD from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). CR3022 targets a highly conserved epitope that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV.
Note: Questions related to NR-52392 may be addressed by contacting info@novicibiotech.com.
NR-52392 is specific to the S glycoprotein and has been shown to neutralize SARS-CoV. CR3022 recognizes the full-length SARS-CoV-2 S1 protein fused to a human IgG1 Fc domain (S1-Fc) under reducing and non-reducing conditions, as well as a hexa-histidine-tagged S glycoprotein RBD alone, in Western blot analysis; however, CR3022 did not neutralize SARS-CoV-2 in a recent in vitro assay. CR3022 binds potently to SARS-CoV-2 RBD as determined by ELISA and biolayer interferometry (BLI) binding assays.
Applications include western blot analysis, immunofluorescence, ELISA and neutralization.
Each vial of NR-52392 contains approximately 50 ?L of purified monoclonal antibody in PBS.
Antibody Class: IgG1
Human monoclonal antibody CR3022 was prepared via an immune phage display library, constructed from lymphocytes of a convalescent severe acute respiratory syndrome coronavirus (SARS-CoV) patient. CR3022 is a neutralizing antibody that targets the receptor binding domain (RBD) of the spike (S) glycoprotein of SARS-CoV. NR-52392 was produced in Nicotiana benthamiana tobacco plants using a transient plant expression system and purified from the extracellular fraction using protein A chromatography. Plant-made antibody CR3022 features complementarity-determining region (CDR) sequences introduced into a human IgG1 molecule. The epitope of CR3022 does not overlap with the ACE2-binding site within the S glycoprotein RBD from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). CR3022 targets a highly conserved epitope that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV.
Note: Questions related to NR-52392 may be addressed by contacting info@novicibiotech.com.
NR-52392 is specific to the S glycoprotein and has been shown to neutralize SARS-CoV. CR3022 recognizes the full-length SARS-CoV-2 S1 protein fused to a human IgG1 Fc domain (S1-Fc) under reducing and non-reducing conditions, as well as a hexa-histidine-tagged S glycoprotein RBD alone, in Western blot analysis; however, CR3022 did not neutralize SARS-CoV-2 in a recent in vitro assay. CR3022 binds potently to SARS-CoV-2 RBD as determined by ELISA and biolayer interferometry (BLI) binding assays.
Applications include western blot analysis, immunofluorescence, ELISA and neutralization.
Each vial of NR-52392 contains approximately 50 ?L of purified monoclonal antibody in PBS.
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
抗体类：IgG1
通过免疫噬菌体展示文库制备人单克隆抗体CR3022，由促进的严重急性呼吸综合征冠状病毒（SARS-COV）患者的淋巴细胞构成. CR3022是靶向SARS-COV的穗糖蛋白的受体结合结构域（RBD）的中和抗体.使用瞬态植物表达系统在尼古特尼沙氨酰胺（烟草植物中）制备NR-52392，并使用蛋白质A色谱法从细胞外级分纯化.植物制造的抗体CR3022具有引入人IgG1分子中的互补确定区域（CDR）序列. CR3022的表位与来自严重急性呼吸综合征相关的冠状病毒2（SARS-COV-2）的S糖蛋白RBD中的ACE2结合位点不重叠. CR3022靶向高度保守的表位，使得SARS-COV-2和SARS-COV之间的交叉反应结合能够.
注意：与NR-52392相关的问题可以通过联系 info@novicibiotech.com">
NR-52392特异于S糖蛋白，已被证明以中和SARS-COV. CR3022识别到在减少和非还原条件下与人IgG1 Fc结构域（S1-Fc）融合的全长SARS-COV-2 S1蛋白，以及单独的六征组氨酸标记的糖蛋白RBD，在Western印迹中分析;然而，CR3022在近期的体外测定中没有中和SARS-COV-2. CR3022效果效果，如ELISA和BIOLAYER干涉测定（BLI）结合测定法所确定的.
应用包括蛋白质印迹分析，免疫荧光，ELISA和中和.
每个小瓶NR-52392在PBS中含有大约50μL纯化的单克隆抗体.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-04-01
2024-01-21
2021-10-31
2019-05-08
2022-04-01
2021-12-21
2022-04-01
2022-04-01
2021-12-21
2022-06-17
2021-12-21
2024-01-21
2024-01-21
2023-11-12
2024-05-19